PharmaIN Corporation and Polypeptide Therapeutic Solutions (PTS) Announce Collaboration Agreement for Contract Manufacturing

Press Release

PharmaIN Corporation and Polypeptide Therapeutic Solutions (PTS) Announce Collaboration Agreement for Contract Manufacturing

 

Bothell, WA & Valencia, Spain – 21st September 2018  PharmaIN Corporation and Polypeptide Therapeutic Solutions (PTS) announced today that they have entered into a collaboration agreement for contract manufacturing.

Under the agreement, Polypeptide Therapeutic Solutions will provide PharmaIN contract research services and own technology to add as a part of PharmaIN´s Protected Graft Co-Polymer (PGCTM) delivery Platform. Within the agreement, PTS will also support PGC® program in terms of GMP grade and large-scale manufacturing of key starting materials for PGC® within PTS´s brand new GMP facilities.

”PTS has been a great partner and we were excited to hear that they were building GMP grade production facilities” commented Dr Elijah Bolotin , CEO of PharmaIN.

”Our pipeline products will require GMP grade components as they enter clinical trials and knowing we can depend on a reliable and responsive partner like PTS gives us confidence on those. PTS has provided PharmaIN with the high-quality polymers of unmatched polydispersity and top-notch analytical support.” commented Dr Sergey Rakhilin, Director of Product Development, PharmaIN.

“We teamed with PharmaIN and were able to deliver a consistent and robust material in less than nine months, helping our partner to reduce time, costs and risks.” says Jose Vicente Pons, Chief Executive Officer at PTS.

“We are very delighted to see the results of the collaboration and to strengthen our relationship with PharmaIN with this agreement” commented Vicent J. Nebot, Chief Technical Officer at PTS.

About PharmaIN
PharmaIN Corporation, headquartered in Bothell, WA, (near Seattle) is developing superior drug therapies by using its “Protected Graft Co-polymer” (PGC™) excipient and innovative peptide engineering technologies to enable effective and safe injectable peptide therapeutics. Besides peptides, PGC excipient can be beneficial to improve PK, bioavailability, stability and solubility of numerous proteins and some poorly soluble potent small molecules. PharmaIN works with partner companies to enable new, value-added drug therapies and improve “old” drugs using these platforms. Visit www.PharmaIN.com.

About Polypeptide Therapeutic Solutions
PTS is a company devoted to the design and manufacture of polypeptide-based materials for drug delivery and high-tech applications. Proprietary know-how & IP to provide a 360º solution from early research, through scale-up to first preclinical batches, analytical solutions within a GLP certified QC laboratory and brand new GMP facility for manufacturing clinical grade polypeptide-based therapeutics. Please visit www.pts-polypeptides.com.